Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.3K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

2.0K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
2.0K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

928
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
928
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tracking the dynamic breakdown of contextual coherence in schizophrenia using language models.

Frontiers in psychiatry·2026
Same author

Genome-wide association study and polygenic risk score analysis for bipolar disorder in the Korean population.

Asian journal of psychiatry·2026
Same author

Perplexity and pseudo-perplexity as objective measures of linguistic deficits in schizophrenia: Evidence from a Korean-Speaking cohort.

Schizophrenia research·2026
Same author

Predictors of conversion to psychosis and mortality in first-episode substance-induced psychosis: a nationwide register-based study in South Korea.

Schizophrenia (Heidelberg, Germany)·2026
Same author

Brain structural abnormalities in treatment-resistant schizophrenia.

Molecular psychiatry·2026
Same author

Altered auditory seed-based functional connectivity in other specified schizophrenia spectrum and other psychotic disorder compared to schizophrenia spectrum disorders.

Schizophrenia (Heidelberg, Germany)·2026
Same journal

Ketamine effects on EEG and their links to therapy differ across treatment-resistant major depression, post-traumatic stress disorder, and obsessive-compulsive disorder.

The international journal of neuropsychopharmacology·2026
Same journal

Genetic overlap between treatment-resistant schizophrenia and smoking initiation.

The international journal of neuropsychopharmacology·2026
Same journal

External Validation as the Critical Step for Predictive Biomarkers.

The international journal of neuropsychopharmacology·2026
Same journal

Viloxazine occupies the 5-HT2C receptor in the macaca fascicularis brain in vivo: A [11C]CIMBI-36 positron emission tomography study.

The international journal of neuropsychopharmacology·2026
Same journal

Divergent effects of interleukin-6 and ghrelin on remission and relapse in depression treatment.

The international journal of neuropsychopharmacology·2026
Same journal

Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program.

The international journal of neuropsychopharmacology·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
06:25

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

10.8K

Hyperprolactinaemia induced by risperidone.

Young-Chul Chung1, Hong-Bai Eun

  • 1Department of Psychiatry, Chonbuk National University School of Medicine, Institute for Medical Science, Chonju, Korea.

The International Journal of Neuropsychopharmacology
|April 3, 2001
PubMed
Summary
This summary is machine-generated.

Risperidone effectively treats psychosis but can increase prolactin levels, especially in female or first-episode patients. This study reports five cases of risperidone-induced hyperprolactinemia in such individuals.

More Related Videos

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K

Related Experiment Videos

Last Updated: May 5, 2026

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
06:25

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

10.8K
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Endocrinology

Background:

  • Risperidone is an atypical antipsychotic effective against positive and negative symptoms of psychosis.
  • It acts as a dopamine D2 and serotonin 5-HT2 receptor antagonist.
  • Common side effects include agitation, anxiety, insomnia, and extrapyramidal symptoms (EPS).

Purpose of the Study:

  • To investigate the endocrine side effects of risperidone.
  • To report cases of risperidone-induced hyperprolactinemia.
  • To identify patient characteristics associated with increased risk.

Main Methods:

  • Review of clinical trial data on risperidone side effects.
  • Case series reporting on patients experiencing hyperprolactinemia.
  • Analysis of patient demographics and drug regimens.

Main Results:

  • Risperidone can elevate prolactin levels, similar to other neuroleptics.
  • Reported incidence of amenorrhea and galactorrhea is low in open trials.
  • Five cases of hyperprolactinemia were observed in female or first-episode psychotic patients.

Conclusions:

  • Hyperprolactinemia is a potential side effect of risperidone.
  • Female patients and those experiencing their first psychotic episode may be at higher risk.
  • Dosage and titration schedules may influence the incidence of endocrine side effects.